Centre for Excellence in Molecular Biology, University of the Punjab, Lahore, Punjab, 53700, Pakistan.
Per Med. 2024;21(3):175-190. doi: 10.1080/17410541.2024.2341610. Epub 2024 May 6.
In the context of cancer heterogeneity, the synergistic action of next-generation sequencing (NGS) and CRISPR/Cas9 plays a promising role in the personalized treatment of cancer. NGS enables high-throughput genomic profiling of tumors and pinpoints specific mutations that primarily lead to cancer. Oncologists use this information obtained from NGS in the form of DNA profiling or RNA analysis to tailor precision strategies based on an individual's unique molecular signature. Furthermore, the CRISPR technique enables precise editing of cancer-specific mutations, allowing targeted gene modifications. Harnessing the potential insights of NGS and CRISPR/Cas9 heralds a remarkable frontier in cancer therapeutics with unprecedented precision, effectiveness and minimal off-target effects.
在癌症异质性的背景下，下一代测序（NGS）和 CRISPR/Cas9 的协同作用在癌症的个性化治疗中发挥了有前途的作用。NGS 能够对肿瘤进行高通量基因组分析，并确定主要导致癌症的特定突变。肿瘤学家将从 NGS 获得的信息以 DNA 分析或 RNA 分析的形式用于根据个体独特的分子特征制定精准策略。此外，CRISPR 技术可以对癌症特异性突变进行精确编辑，从而实现靶向基因修饰。利用 NGS 和 CRISPR/Cas9 的潜在见解，为癌症治疗带来了前所未有的精准性、有效性和最小的脱靶效应的显著前沿。
